Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

21. Canadian Urological Association (CUA) -Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC)

, the guideline attempts to provide expert opinion to aid in the management of patients. Levels of evidence and grades of recommendation employ the International Consultation on Urologic Disease (ICUD)/ WHO modified Oxford Center for Evidence-Based Medicine grading system. Based on a modified GRADE methodology, the strength of each recommendation is represented by the words STRONG or WEAK. Introduction Castration-resistant prostate cancer (CRPC) is defined by dis - ease progression despite castrate levels (...) of testosterone and may present as either a continuous rise in serum prostate- specific antigen (PSA) levels, the progression of pre-existing disease, and/or the appearance of new metastases. Advanced prostate cancer has been known under a few names over the years, including hormone-resistant prostate can - cer (HRPC) and androgen-insensitive prostate cancer (AIPC). Most recently, the terms castration-resistant prostate cancer or castration-recurrent prostate cancer were introduced with the realization

2019 Canadian Urological Association

22. High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness (...) and Cost-Effectiveness High Dose Rate Brachytherapy versus Low Dose Rate Brachytherapy for the Treatment of Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: February 14, 2019 Project Number: RC1070-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of high-dose-rate versus low-dose-rate brachytherapy for the treatment of prostate cancer? What

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

23. Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Hydrogel Spacers for Patients with Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated (...) : February 22, 2019 Project Number: RC1069-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of hydrogel spacers for patients with prostate cancer? What is the cost-effectiveness of hydrogel spacers for patients with prostate cancer? Key Message Three systematic reviews, one randomized controlled trial (described within two eligible reports), seven cohort studies, two economic evaluations

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

24. Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness

Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Androgen Receptor Targeted Agents for Castration Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Androgen Receptor Targeted Agents for Castration (...) Resistant Prostate Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness Last updated: June 6, 2019 Project Number: RC1127-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of varying treatment sequences of androgen receptor targeted agents in patients with castrate-resistant prostate cancer? What is the comparative cost-effectiveness of varying treatment sequences of androgen

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

25. Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details

Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details | CADTH.ca Find the information you need Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details Darolutamide (TBD) for Non-Metastatic Castration Resistant Prostate Cancer – Details Project Number pCODR 10196 Brand Name TBD Generic Name Darolutamide Tumour Type Genitourinary Indication Non (...) -Metastatic Castration Resistant Prostate Cancer Funding Request In combination with androgen depravation therapy (ADT), for the treatment of patients with non-metastatic castration resistant prostate cancer who are at high risk of developing metastases (high risk defined as prostate-specific antigen doubling time ≤ 10 months) during continuous ADT, and have a good Eastern Cooperative Oncology Group (ECOG) performance status Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Bayer Inc

2019 CADTH - Pan Canadian Oncology Drug Review

26. Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details

Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details | CADTH.ca Find the information you need Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details Apalutamide (Erleada) for Metastatic Castration-Sensitive Prostate Cancer - Details Project Number pCODR 10200 Brand Name Erleada Generic Name Apalutamide Tumour Type Genitourinary Indication Metastatic (...) Castration-Sensitive Prostate Cancer Funding Request For the treatment of metastatic castration-sensitive prostate cancer (mCSPC) Review Status Pending Pre Noc Submission Yes NOC Date Manufacturer Janssen Inc. Sponsor Janssen Inc. Submission Date (Target Date) October 15, 2019 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date) ‡ October 29, 2019 Check-point meeting (target date) pERC Meeting (target date) Initial Recommendation

2019 CADTH - Pan Canadian Oncology Drug Review

27. Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details

Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details | CADTH.ca Find the information you need Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Project Number pCODR 10201 Brand Name Zytiga (Resubmission) Generic Name Abiraterone Strength 250 mg & 500 mg Tumour Type Genitourinary Indication Prostate Cancer Funding Request Newly diagnosed high (...) -risk metastatic castration sensitive prostate cancer without small-cell histologic features. Patients required to have at least two of the three following high-risk factors: Gleason score of 8 or more, at least 3 bone lesions, and presence of visceral metastasis. Less than 3 months of androgen deprivation therapy (or orchiectomy) for metastatic disease. Eligible for abiraterone therapy. Review Status Under Review Pre Noc Submission No NOC Date February 15, 2018 Manufacturer Janssen Inc. Sponsor BC

2019 CADTH - Pan Canadian Oncology Drug Review

28. Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details

Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details | CADTH.ca Find the information you need Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Project Number pCODR 10149 Brand Name Xtandi Generic Name Enzalutamide Strength 40 mg Tumour Type Genitourinary Indication Non-metastatic castration-resistant (...) prostate cancer Funding Request High risk, non-metastatic castration-resistant prostate cancer Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date December 20, 2018 Manufacturer Astellas Pharma Canada, Inc. Sponsor Astellas Pharma Canada, Inc. Submission Date September 24, 2018 Submission Deemed Complete October 9, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline ‡ October 9, 2018 Check-point meeting November 20, 2018 pERC Meeting

2019 CADTH - Pan Canadian Oncology Drug Review

29. Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines

Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines Last updated: September 5, 2019 Project Number (...) : RA1061-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of radical prostatectomy for early-stage or screen-detected prostate cancer? What is the clinical effectiveness of radiation therapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of radical prostatectomy for prostate cancer? What are the evidence-based guidelines on the use of radiation therapy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

30. Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines

Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Last updated: October 3, 2019 Project Number: RA1062-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What (...) is the clinical effectiveness of cryotherapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of cryotherapy for prostate cancer? Key Message Four systematic reviews (including one systematic review with meta-analysis) were identified regarding the clinical effectiveness of cryotherapy for early-stage or screen-detected prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of cryotherapy for prostate cancer. Files

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

31. Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines

Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines | CADTH.ca Find the information you need Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Last updated: August 22, 2019 Project Number: RA1060-000 Product Line: Research Type: Devices and Systems (...) Report Type: Reference List Result type: Report Question What is the clinical utility of prostate-specific antigen testing for prostate cancer? What are the evidence-based guidelines on the use of prostate-specific antigen testing for prostate cancer screening? Key Message Two systematic reviews were identified regarding the clinical utility of prostate-specific antigen testing for prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of prostate-specific

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

32. Enzalutamide (Xtandi) - castration-resistant prostate cancer (CRPC)

with enzalutamide should be initiated and supervised by specialist physicians experienced in the medical treatment of prostate cancer. 1 Product availability date 23 October 2018 Enzalutamide meets SMC orphan equivalent criteria for this indication. Summary of evidence on comparative efficacy Enzalutamide is an androgen receptor inhibitor that blocks several stages in the androgen receptor signalling pathway to decrease the growth of prostate cancer cells and it can induce cancer cell death and tumour (...) and clinician engagement (PACE) meeting with patient group representatives and clinical specialists was held to consider the added value of enzalutamide, as an orphan-equivalent medicine, in the context of treatments currently available in NHSScotland. The key points expressed by the group were: ? Although prostate cancer is a common cancer in men, the number of patients with high- risk non-metastatic CRPC is very small. This is an incurable condition that will progress to metastatic disease. The impact

2019 Scottish Medicines Consortium

33. Zytiga for Prostate Cancer – Details

Zytiga for Prostate Cancer – Details Zytiga for Prostate Cancer – Details | CADTH.ca Find the information you need Zytiga for Prostate Cancer – Details Zytiga for Prostate Cancer – Details Project Number pCODR 10166 Brand Name Zytiga Generic Name Abiraterone Strength 250 mg & 500 mg Tumour Type Genitourinary Indication Prostate Cancer Funding Request Newly diagnosed with metastatic prostate cancer without small-cell histologic features (may have received prior surgery or radiation therapy (...) for local disease or palliative therapy); Less than 3 months of androgen deprivation therapy for metastatic disease (may have received prior adjuvant/neoadjuvant hormone therapy); Eligible for abiraterone therapy Review Status Withdrawn Clarification BC Cancer Agency has requested a voluntary withdrawal of the pCODR 10166 Abiraterone (Zytiga) for PC Submission. As per pCODR Procedures B3.1.6.2 b), the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue

2019 CADTH - Pan Canadian Oncology Drug Review

34. Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report

. The responsibility for the contents of the report lies solely with IQWiG. IQWiG employees ? Christoph Mosch ? Daniel Fleer ? Marco Knelangen ? Sibylle Sturtz Keywords: Brachytherapy, Prostatic Neoplasms, Benefit Assessment, Systematic Review Extract of rapid report N17-04 Version 1.0 Brachytherapy for prostate cancer 19 October 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Key statement Research question The aim of this report is to ? update the benefit assessment of treatment (...) Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report 1 Translation of the key statement of the rapid report N17-04 Interstitielle Low-Dose-Rate-Brachytherapie beim lokal begrenzten Prostatakarzinom (Version 1.0; Status: 19 October 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

35. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. (Abstract)

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear.We randomly assigned, in a 1:1 ratio, patients who had (...) with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen-signaling-targeted agent (abiraterone or enzalutamide). (Funded by Sanofi; CARD ClinicalTrials.gov number, NCT02485691.).Copyright © 2019 Massachusetts Medical Society.

2019 NEJM

36. Risk of prostate cancer for men fathering through assisted reproduction: nationwide population based register study. Full Text available with Trip Pro

 618 by in vitro fertilisation (IVF), 14 882 by intra-cytoplasmic sperm injection (ICSI), and 1 145 990 by natural conception.Prostate cancer diagnosis, age of onset, and androgen deprivation therapy (serving as proxy for advanced or metastatic malignancy).Among men achieving fatherhood by IVF, by ICSI, and by non-assisted means, 77 (0.37%), 63 (0.42%), and 3244 (0.28%), respectively, were diagnosed as having prostate cancer. Mean age at onset was 55.9, 55.1, and 57.1 years, respectively. Men who (...) became fathers through assisted reproduction had a statistically significantly increased risk of prostate cancer compared with men who conceived naturally (hazard ratio 1.64, 95% confidence interval 1.25 to 2.15, for ICSI; 1.33, 1.06 to 1.66, for IVF). They also had an increased risk of early onset disease (that is, diagnosis before age 55 years) (hazard ratio 1.86, 1.25 to 2.77, for ICSI; 1.51, 1.09 to 2.08, for IVF). Fathers who conceived through ICSI and developed prostate cancer received androgen

2019 BMJ

37. Hypofractionation for clinically localized prostate cancer. (Abstract)

Hypofractionation for clinically localized prostate cancer. Using hypofractionation (fewer, larger doses of daily radiation) to treat localized prostate cancer may improve convenience and resource use. For hypofractionation to be feasible, it must be at least as effective for cancer-related outcomes and have comparable toxicity and quality of life outcomes as conventionally fractionated radiation therapy.To assess the effects of hypofractionated external beam radiation therapy compared (...) prostate adenocarcinoma where hypofractionated radiation therapy (external beam radiation therapy) to the prostate using hypofractionation (greater than 2 Gy per fraction) compared with conventionally fractionated radiation therapy to the prostate delivered using standard fractionation (1.8 Gy to 2 Gy per fraction).We used standard Cochrane methodology. Two authors independently assessed trial quality and extracted data. We used Review Manager 5 for data analysis and meta-analysis. We used the inverse

2019 Cochrane

38. Daily online image-guided radiotherapy for people undergoing radical prostate cancer treatment

Daily online image-guided radiotherapy for people undergoing radical prostate cancer treatment Daily online image-guided radiotherapy (prostate cancer) - Health Technology Wales > Daily online image-guided radiotherapy (prostate cancer) Daily online image-guided radiotherapy (prostate cancer) Topic Status Complete Daily online image-guided radiotherapy for people undergoing radical prostate cancer treatment. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale (...) University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER038 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend

2019 Health Technology Wales

39. Darolutamide (Nubeqa) - adult patients with non-metastatic castration resistant prostate cancer

Darolutamide (Nubeqa) - adult patients with non-metastatic castration resistant prostate cancer Drug Approval Package: NUBEQA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: NUBEQA Company: Bayer HealthCare Pharmaceuticals Inc. Application Number: 212099 Approval Date: 07/30/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

2019 FDA - Drug Approval Package

40. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension Full Text available with Trip Pro

Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension It remains unclear whether patients with positive surgical margins or extracapsular extension benefit from adjuvant radiotherapy following radical prostatectomy.To compare the effectiveness and tolerability of adjuvant radiotherapy following radical prostatectomy.This was a randomised, open-label, parallel-group (...) alone in patients with positive margins or extracapsular extension.Radiotherapy given immediately after prostate cancer surgery prolongs prostate-specific antigen progression-free survival, but causes more adverse events, when compared with surgery alone.Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2019 EvidenceUpdates